The effect of statins on mortality in heart failure with preserved ejection fraction: A meta-analysis of propensity score analyses

International Journal of Cardiology

Volumn 214, Issue , 2016, Pages 301-306

  Fukuta, Hidekatsu ^a   Goto, Toshihiko ^a   Wakami, Kazuaki ^a   Ohte, Nobuyuki ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

heart failure with preserved ejection fraction; meta analysis; propensity score analysis; statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERTENSION; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROPENSITY SCORE; SURVIVAL RATE; AGED; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MALE; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; SURVIVAL ANALYSIS;

AGED; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; OBSERVATIONAL STUDIES AS TOPIC; PROPENSITY SCORE; PROSPECTIVE STUDIES; STROKE VOLUME; SURVIVAL ANALYSIS; VENTRICULAR FUNCTION, LEFT;

EID: 84963626029     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.03.186     Document Type: Article

References (64)

1. R.S. Vasan, M.G. Larson, E.J. Benjamin, J.C. Evans, C.K. Reiss, and D. Levy Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort J. Am. Coll. Cardiol. 33 1999 1948 1955
2. T.E. Owan, D.O. Hodge, R.M. Herges, S.J. Jacobsen, V.L. Roger, and M.M. Redfield Trends in prevalence and outcome of heart failure with preserved ejection fraction N. Engl. J. Med. 355 2006 251 259
3. M. Tsuchihashi-Makaya, S. Hamaguchi, S. Kinugawa, T. Yokota, D. Goto, H. Yokoshiki, and et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report From the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) Circ. J. 73 2009 1893 1900
4. B.M. Massie, P.E. Carson, J.J. McMurray, M. Komajda, R. McKelvie, M.R. Zile, and et al. Irbesartan in patients with heart failure and preserved ejection fraction N. Engl. J. Med. 359 2008 2456 2467
5. J.G. Cleland, M. Tendera, J. Adamus, N. Freemantle, L. Polonski, and J. Taylor The perindopril in elderly people with chronic heart failure (PEP-CHF) study Eur. Heart J. 27 2006 2338 2345
6. B. Pitt, M.A. Pfeffer, S.F. Assmann, R. Boineau, I.S. Anand, B. Claggett, and et al. Spironolactone for heart failure with preserved ejection fraction N. Engl. J. Med. 370 2014 1383 1392
7. K. Yamamoto, H. Origasa, and M. Hori Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF) Eur. J. Heart Fail. 15 2013 110 118
8. H. Akahori, T. Tsujino, Y. Naito, M. Matsumoto, N. Sasaki, T. Iwasaku, and et al. Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats J. Hypertens. 32 2014 1534 1541
9. D. Gomez-Garre, M.L. Gonzalez-Rubio, P. Munoz-Pacheco, A. Caro-Vadillo, P. Aragoncillo, and A. Fernandez-Cruz Rosuvastatin added to standard heart failure therapy improves cardiac remodelling in heart failure rats with preserved ejection fraction Eur. J. Heart Fail. 12 2010 903 912
10. R. Patel, S.F. Nagueh, N. Tsybouleva, M. Abdellatif, S. Lutucuta, H.A. Kopelen, and et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy Circulation 104 2001 317 324
11. C. Indolfi, L.E. Di, C. Perrino, A.M. Stingone, A. Curcio, D. Torella, and et al. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation Circulation 106 2002 2118 2124
12. J. Davignon Beneficial cardiovascular pleiotropic effects of statins Circulation 109 2004 III39 III43
13. U. Landmesser, F. Bahlmann, M. Mueller, S. Spiekermann, N. Kirchhoff, S. Schulz, and et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans Circulation 111 2005 2356 2363
14. K.E. Ferrier, M.H. Muhlmann, J.P. Baguet, J.D. Cameron, G.L. Jennings, A.M. Dart, and et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension J. Am. Coll. Cardiol. 39 2002 1020 1025
15. T.J. Smilde, F.W. van den Berkmortel, H. Wollersheim, H. van L, J.J. Kastelein, and A.F. Stalenhoef The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia Eur. J. Clin. Investig. 30 2000 473 480
16. L. Zhang, S. Zhang, H. Jiang, A. Sun, Y. Wang, Y. Zou, and et al. Effects of statin therapy on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials Arch. Med. Res. 41 2010 464 471
17. M.R. Zile, and D.L. Brutsaert New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment Circulation 105 2002 1503 1508
18. M. Senni, W.J. Paulus, A. Gavazzi, A.G. Fraser, J. Diez, S.D. Solomon, and et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes Eur. Heart J. 35 2014 2797 2815
19. H. Fukuta, D.C. Sane, S. Brucks, and W.C. Little Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report Circulation 112 2005 357 363
20. M. Roik, M.H. Starczewska, Z. Huczek, J. Kochanowski, and G. Opolski Statin therapy and mortality among patients hospitalized with heart failure and preserved left ventricular function-a preliminary report Acta Cardiol. 63 2008 683 692
21. R. Shah, Y. Wang, and J.M. Foody Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients > or = 65 years of age with heart failure and preserved left ventricular systolic function Am. J. Cardiol. 101 2008 217 222
22. M. Ouzounian, J.V. Tu, P.C. Austin, A. Chong, P.P. Liu, and D.S. Lee Statin therapy and clinical outcomes in heart failure: a propensity-matched analysis J. Card. Fail. 15 2009 241 248
23. F. Tehrani, R. Morrissey, A. Phan, C. Chien, and E.R. Schwarz Statin therapy in patients with diastolic heart failure Clin. Cardiol. 33 2010 E1 E5
24. L.R. Quiros, A.J. Garcia, E. Martin, S.J. Trujillo, M.A. Villena Ruiz, and M.E. Perea Prognostic factors and long-term survival after initial diagnosis of heart failure Med. Clin. (Barc.) 138 2012 602 608
25. H. Kaneko, S. Suzuki, J. Yajima, Y. Oikawa, K. Sagara, T. Otsuka, and et al. Clinical characteristics and long-term clinical outcomes of Japanese heart failure patients with preserved versus reduced left ventricular ejection fraction: a prospective cohort of Shinken Database 2004-2011 J. Cardiol. 62 2013 102 109
26. G. Liu, X.X. Zheng, Y.L. Xu, J. Ru, R.T. Hui, and X.H. Huang Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction Am. J. Cardiol. 113 2014 1198 1204
27. J.S. Haukoos, and R.J. Lewis The Propensity Score JAMA 314 2015 1637 1638
28. O. Kuss von SB, Borgermann J: Off-pump versus on-pump coronary artery bypass grafting: a systematic review and meta-analysis of propensity score analyses J. Thorac. Cardiovasc. Surg. 140 2010 829 835 (835)
29. K. Nochioka, Y. Sakata, S. Miyata, M. Miura, T. Takada, S. Tadaki, and et al. Prognostic impact of statin use in patients with heart failure and preserved ejection fraction Circ. J. 79 2015 574 582
30. U. Alehagen, L. Benson, M. Edner, U. Dahlstrom, and L.H. Lund Association Between Use of Statins and Mortality in Patients With Heart Failure and Ejection Fraction of >/=50 Circ. Heart Fail. 8 2015 862 870
31. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann. Intern. Med. 151 2009 264 269 (W64)
32. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
33. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
34. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group N. Engl. J. Med. 339 1998 1349 1357
35. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, and et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N. Engl. J. Med. 335 1996 1001 1009
36. G.N. Levine, J.F. Keaney Jr., and J.A. Vita Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms N. Engl. J. Med. 332 1995 512 521
37. R. Collins, J. Armitage, S. Parish, P. Sleigh, and R. Peto MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
38. G.P. Aurigemma, and W.H. Gaasch Clinical practice. Diastolic heart failure N. Engl. J. Med. 351 2004 1097 1105
39. M.M. Redfield Understanding "diastolic" heart failure N. Engl. J. Med. 350 2004 1930 1931
40. D.J. Farrar, H.D. Green, W.D. Wagner, and M.G. Bond Reduction in pulse wave velocity and improvement of aortic distensibility accompanying regression of atherosclerosis in the rhesus monkey Circ. Res. 47 1980 425 432
41. R. Corti, V. Fuster, Z.A. Fayad, S.G. Worthley, G. Helft, D. Smith, and et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging Circulation 106 2002 2884 2887
42. M.F. O'Rourke Diastolic heart failure, diastolic left ventricular dysfunction and exercise intolerance J. Am. Coll. Cardiol. 38 2001 803 805
43. D.A. Kass, J.G. Bronzwaer, and W.J. Paulus What mechanisms underlie diastolic dysfunction in heart failure? Circ. Res. 94 2004 1533 1542
44. J. Bauersachs, P. Galuppo, D. Fraccarollo, M. Christ, and G. Ertl Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction Circulation 104 2001 982 985
45. S. Hayashidani, H. Tsutsui, T. Shiomi, N. Suematsu, S. Kinugawa, T. Ide, and et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction Circulation 105 2002 868 873
46. V. Zaca, S. Rastogi, M. Imai, M. Wang, V.G. Sharov, A. Jiang, and et al. Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure J. Am. Coll. Cardiol. 50 2007 551 557
47. M. Saka, K. Obata, S. Ichihara, X.W. Cheng, H. Kimata, T. Nishizawa, and et al. Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure J. Cardiovasc. Pharmacol. 47 2006 770 779
48. S. Ichihara, A. Noda, K. Nagata, K. Obata, J. Xu, G. Ichihara, and et al. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure Cardiovasc. Res. 69 2006 726 735
49. Y. Young-Xu, S. Jabbour, R. Goldberg, C.M. Blatt, T. Graboys, B. Bilchik, and et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease Am. J. Cardiol. 92 2003 1379 1383
50. C.W. Siu, C.P. Lau, and H.F. Tse Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion Am. J. Cardiol. 92 2003 1343 1345
51. G. Patti, M. Chello, D. Candura, V. Pasceri, A. D'Ambrosio, E. Covino, and et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study Circulation 114 2006 1455 1461
52. K.H. Humphries, M. Lee, R. Sheldon, K. Ramanathan, P. Dorian, M. Green, and et al. Statin use and recurrence of atrial fibrillation after successful cardioversion Am. Heart J. 154 2007 908 913
53. L.B. Mitchell, J.L. Powell, A.M. Gillis, V. Kehl, and A.P. Hallstrom Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial J. Am. Coll. Cardiol. 42 2003 81 87
54. A.K. Vyas, H. Guo, A.J. Moss, B. Olshansky, S.A. McNitt, W.J. Hall, and et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II J. Am. Coll. Cardiol. 47 2006 769 773
55. A. Deswal, N.J. Petersen, A.M. Feldman, J.B. Young, B.G. White, and D.L. Mann Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST) Circulation 103 2001 2055 2059
56. M. Rauchhaus, W. Doehner, D.P. Francis, C. Davos, M. Kemp, C. Liebenthal, and et al. Plasma cytokine parameters and mortality in patients with chronic heart failure Circulation 102 2000 3060 3067
57. M.M. Givertz, and W.S. Colucci New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress Lancet 352 Suppl. 1 1998 SI34 SI38
58. L.G. Olsson, K. Swedberg, A. Ducharme, C.B. Granger, E.L. Michelson, J.J. McMurray, and et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program J. Am. Coll. Cardiol. 47 2006 1997 2004
59. S.D. Solomon, D. Wang, P. Finn, H. Skali, L. Zornoff, J.J. McMurray, and et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program Circulation 110 2004 2180 2183
60. S.D. Solomon, N. Anavekar, H. Skali, J.J. McMurray, K. Swedberg, S. Yusuf, and et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients Circulation 112 2005 3738 3744
61. J. Kjekshus, E. Apetrei, V. Barrios, M. Bohm, J.G. Cleland, J.H. Cornel, and et al. Rosuvastatin in older patients with systolic heart failure N. Engl. J. Med. 357 2007 2248 2261
62. L. Tavazzi, A.P. Maggioni, R. Marchioli, S. Barlera, M.G. Franzosi, R. Latini, and et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 1231 1239
63. K.O. Bonsu, D.D. Reidpath, and A. Kadirvelu Effects of Statin Treatment on Inflammation and Cardiac function in Heart Failure: An Adjusted Indirect Comparison Meta-analysis of Randomised Trials Cardiovasc. Ther. 2015
64. G. Liu, X.X. Zheng, Y.L. Xu, J. Lu, R.T. Hui, and X.H. Huang Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials Heart Lung Circ. 23 2014 970 977